Functional benefits of PLGA particulates carrying VEGF and CoQ10 in an animal of myocardial ischemia

Myocardial ischemia (MI) remains one of the leading causes of death worldwide. Angiogenic therapy with the vascular endothelial growth factor (VEGF) is a promising strategy to overcome hypoxia and its consequences. However, from the clinical data it is clear that fulfillment of the potential of VEGF...

Full description

Saved in:
Bibliographic Details
Published in:International journal of pharmaceutics 2013-10, Vol.454 (2), p.784-790
Main Authors: Simón-Yarza, Teresa, Tamayo, Esther, Benavides, Carolina, Lana, Hugo, Formiga, Fabio R., Grama, Charitra N., Ortiz-de-Solorzano, Carlos, Kumar, M.N.V. Ravi, Prosper, Felipe, Blanco-Prieto, Maria J.
Format: Article
Language:English
Subjects:
Angiogenesis
Animals
antioxidants
cardiac output
Cell Proliferation - drug effects
CoQ10
Coronary Vessels - drug effects
Coronary Vessels - physiology
death
Disease Models, Animal
electron transport chain
Female
Human Umbilical Vein Endothelial Cells - cytology
Human Umbilical Vein Endothelial Cells - drug effects
Humans
hypoxia
Lactic Acid - chemistry
mitochondria
Myocardial ischemia
Myocardial Ischemia - drug therapy
Myocardial Ischemia - pathology
Myocardial Ischemia - physiopathology
Myocardium - pathology
nanoparticles
Nanoparticles - administration & dosage
Nanoparticles - chemistry
Neovascularization, Physiologic - drug effects
oxidative stress
particulates
pharmacokinetics
Polyglycolic Acid - chemistry
Protein delivery
Rats
Rats, Sprague-Dawley
Recombinant Proteins - administration & dosage
Recombinant Proteins - chemistry
Stroke Volume - drug effects
synergism
therapeutics
Tissue engineering
Ubiquinone - administration & dosage
Ubiquinone - analogs & derivatives
Ubiquinone - chemistry
Vascular Endothelial Growth Factor A - administration & dosage
Vascular Endothelial Growth Factor A - chemistry
Vascular Endothelial Growth Factor A - genetics
vascular endothelial growth factors
VEGF
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Myocardial ischemia (MI) remains one of the leading causes of death worldwide. Angiogenic therapy with the vascular endothelial growth factor (VEGF) is a promising strategy to overcome hypoxia and its consequences. However, from the clinical data it is clear that fulfillment of the potential of VEGF warrants a better delivery strategy. On the other hand, the compelling evidences of the role of oxidative stress in diseases like MI encourage the use of antioxidant agents. Coenzyme Q10 (CoQ10) due to its role in the electron transport chain in the mitochondria seems to be a good candidate to manage MI but is associated with poor biopharmaceutical properties seeking better delivery approaches. The female Sprague Dawley rats were induced MI and were followed up with VEGF microparticles intramyocardially and CoQ10 nanoparticles orally or their combination with appropriate controls. Cardiac function was assessed by measuring ejection fraction before and after three months of therapy. Results demonstrate significant improvement in the ejection fraction after three months with both treatment forms individually; however the combination therapy failed to offer any synergism. In conclusion, VEGF microparticles and CoQ10 nanoparticles can be considered as promising strategies for managing MI.
ISSN:0378-5173
1873-3476
DOI:10.1016/j.ijpharm.2013.04.015